Comparison of Domestic Reagents and Roche COBAS TaqMan in Rapid and Early Virological Response in Patients with Chronic Hepatitis C

WANG Jian,JIN Qian,RAO Hui-ying,YANG Rui-feng,ZHANG Hai-ying,GUO Fang,CHEN Xin-yue,XU Xiao-yuan,YOU Hong,WEI Lai
DOI: https://doi.org/10.3969/j.issn.1007-8134.2012.03.015
2012-01-01
Abstract:Objective To evaluate the determination of rapid virological response (RVR) and early virological response ( EVR) by detecting the serum samles of paitents with chronic hepatitis C (CHC) with generic real-time quantitative PCR kits (domestic reagents) and Roche COBASAmpliPrep/COBASTaqMan48(Roche COBAS TaqMan) and investigate the application value of do-mestic reagents in the treatment of CHC. Methods Serum samples were collected from 223 CHC patients before treatment and at week 4 and 12 of treatment. Roche COBAS TaqMan and domestic reagents were used to detect HCV RNA. The determination of RVR and EVR with the two reagents were compared and analyzed. Results HCV RNA was (6.24±0.97) log10 (Roche COBAS Taq-Man) before treatment in 223 CHC patients. False negative rate for the determination of RVR with domestic reagents was 37.3% (95% confidence interval 26.4%~48.6%), and that for the determination of EVR was 20.8% (95% confidence interval 4.6%~37.0%). At week 4 of treatment, HCV RNA was not detected in 28 patients with domestic reagents. The serum samples of the 28 paitents were detected with Roche COBAS TaqMan at week 12 and it was found that HCV RNA was not detected in 27 patients and was 2.78 log10 in one patient. Conclusions It is suggested that the reagents with high sensitivity should be used to detect HCV RNA at week 4 and 12 of treatment. If HCV RNA was not detected with domestic reagents at week 4, it can be concluded that the patients can achieve EVR and the treatment duration can be decided according to EVR.
What problem does this paper attempt to address?